Details for Patent: 6,169,100
✉ Email this page to a colleague
Title: | Pharmaceutical composition |
Abstract: | Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes. |
Inventor(s): | Ikeda; Hitoshi (Higashiosaka, JP), Sohda; Takashi (Takatsuki, JP), Odaka; Hiroyuki (Kobe, JP) |
Assignee: | Takeda Chemical Industries, Ltd. (Osaka, JP) |
Filing Date: | Aug 31, 1999 |
Application Number: | 09/386,504 |
Claims: | 1. A method for reducing the side effects of active components administered to a diabetic patient which comprises administering to said patient a therapeutically effective amount of an insulin sensitivity enhancer in combination with a statin compound. 2. The method according to claim 1, wherein the insulin sensitivity enhancer is pioglitazone or its hydrochloride. 3. The method according to claim 1, wherein the insulin sensitivity enhancer is troglitazone. 4. The method according to claim 1, wherein the insulin sensitivity enhancer is pharmacologically acceptable salt. 5-[[4-[2(methyl-2-pyridylamino)ethoxy]-methyl]-2,4-thiazolidinedione or its 5. The method according to claim 1, wherein the statin compound is selected from the group consisting of pravastatin and its sodium salt, simvastatin, lovastatin, atorvastatin and fluvastatin. 6. The method according to claim 1, wherein the insulin sensitivity enhancer and statin compound are mixed together to form an admixture and the admixture is administered to the mammal. 7. The method according to claim 1, wherein the insulin sensitivity enhancer and statin compound are not mixed together but are administered independently to the mammal. 8. The method according to claim 1, wherein the statin compound is pravastatin or its sodium salt. 9. The method according to claim 1, wherein the statin compound is simvastatin. 10. The method according to claim 1, wherein the statin compound is lovatatin. 11. The method according to claim 1, wherein the statin compound is atorvastatin. 12. The method according to claim 1, wherein the statin compound is fluvatatin. |